C
보로노이
310210KOSDAQ자연과학 및 공학 연구개발업46.0 / 100
Reference Date: 2026-04-13
Financial Score12.5 / 40
News Sentiment12.5 / 25
Momentum11.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Plunged 21.1% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Boronoai is a biotech company specializing in the development of targeted therapies for cancers such as lung and breast cancer, leveraging its in-house research facilities and AI platforms to conduct early clinical trials and pursue a global licensing-out (License-Out) business model. The company focuses on kinase inhibitors, leveraging its expertise and accelerated development timelines to build competitive pipelines.
Number of Employees
149people
Average Salary
81.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
—Industry Average 3.823.5Point
ROE
-50.18Industry Average -32.113.5Point
1.6x industry avg (good)
Debt Ratio
57.37Industry Average 7.520.0Point
7.6x industry avg (risky)
Trend 2023~20251.5 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
0.0 / 3
Avg ▼32.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -52.7% (improving, 3yr)
Detailed News Sentiment
7 totalPositive 0Neutral 2Negative 0Average Sentiment Score 50
- Neutral
- Neutral
Detailed Momentum
52-week position6.0Point
52w upper range (71%)
Current 287,000Won52-week high 363,50052-week low 91,700
1-month return0.0Point
1m -21.05% (strong drop)
Volume trend5.0Point
Volume increasing
Detailed Disclosure
7 totalPositive 0Neutral 7Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-04-03
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30
- Neutral정기주주총회결과2026-03-30
- Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (VRN101099의 제1상 임상시험계획 승인)2026-03-27
- Neutral투자판단관련주요경영사항(임상시험계획변경승인) (VRN110755의 제 1/2상 임상시험)2026-03-26